Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747613 | 0.97 | CACNA2D1 (0.62) | CACNA2D1SLC6A2 | |
| SCHEMBL20970771 | 0.88 | CACNA2D1 (0.61) | CACNA2D1SLC6A2 | |
| SCHEMBL21770725 | 0.88 | CACNA2D1 (0.74) | CACNA2D1SLC6A2 | |
| SCHEMBL20970675 | 0.88 | CACNA2D1 (0.61) | CACNA2D1SLC6A2 | |
| SCHEMBL20970715 | 0.87 | CACNA2D1 (0.59) | CACNA2D1SLC6A2 | |
| SCHEMBL21747615 | 0.87 | CACNA2D1 (0.66) | CACNA2D1SLC6A2 | |
| SCHEMBL21747611 | 0.86 | CACNA2D1 (0.60) | CACNA2D1SLC6A2 | |
| SCHEMBL19553003 | 0.86 | SLC6A2 (0.83) | CACNA2D1SLC6A2 | |
| SCHEMBL20970791 | 0.85 | CACNA2D1 (0.62) | CACNA2D1SLC6A2 | |
| SCHEMBL21747618 | 0.84 | CACNA2D1 (0.76) | CACNA2D1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452475-B1 | TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2020-02-26 | — | — | EP | claimed |
| US-10590140-B2 | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190144455-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144455-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1G, CACNA1B, CACNA1D | CACNA2D1 12/4885SLC6A2 83/4885 |
| US-10590140-B2 | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | CACNA1G, CACNA1B, CACNA1D | CACNA2D1 12/4885SLC6A2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.